Cybin Inc (HELP.NE) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA23256X4075
Cybin Inc financials
| Fiscal year | 2024 |
|---|---|
| Net income | -78.08 m CAD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cybin Inc
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
More stocks
- ORAGENICS INC (OGEN)
- Eline Entertainment Group, Inc. (EEGI)
- Adagio Medical Holdings, Inc. (ADGM)
- Nexentis Technologies Inc. (NXTS)
- Lunai Bioworks Inc. (LNAI)
- ProtoKinetix, Inc. (PKTX)
- Protagenic Therapeutics, Inc.\new (PTIX)
- CEMTREX INC (CETX)
- Mentor Capital, Inc. (MNTR)
- Karyopharm Therapeutics Inc. (KPTI)
- Catheter Precision, Inc. (VTAK)
- My Size, Inc. (MYSZ)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.